As President and Chief Executive Officer of Porosome Therapeutics Inc., Gil Marmol applies his broad and unique wealth of successful strategic planning, development and operations experience to bring groundbreaking science and technology to market to treat previously intractable and undruggable conditions.
Prior to joining Porosome Therapeutics in 2021, Mr. Marmol served as a member of the executive committee that led the successful turnaround of EDS. While at EDS, Mr. Marmol was responsible for planning, operations improvement, and corporate development, he also led the acquisition of MphasiS a major Indian technology services provider.
He also was Chair of the Operating Committee of Perot Systems Corporation through a period of three-fold growth that included the successful integration of what, at the time, was the largest outsourcing contract in industry history.
Mr. Marmol served as a director (senior partner) of McKinsey & Company. During his 18-year career with McKinsey, he assisted several high-performance organizations in the formulation and execution of growth strategies, which resulted in far above peer group performance. His work in organizational design has been recognized in a variety of publications including the Wall Street Journal.
Mr. Marmol serves on the board of Foot Locker Inc., the leading retailer of athletically inspired footwear and apparel, where he chairs the audit committee. Working in conjunction with leading private equity firms, Mr. Marmol invests and advises early-stage technology companies through his own firm Marmol & Associates.
Mr. Marmol has a BA in Engineering and Applied Physics, Magna Cum Laude, from Harvard College, and an MBA with distinction from the Harvard Business School. He also serves as the chairman of the board of trustees of the Center for a Free Cuba.